This is the sixth multiple ROC solution win for Subex in the Middle East
Subex Ltd has been selected to provide its industry leading revenue operations centre (ROC) fraud management and revenue assurance solutions to the leading Middle Eastern mobile operator.
This is the sixth multiple ROC solution win for Subex in the Middle East. The wide range of Subex references in the region as well as Subex's expertise in the fraud management and revenue assurance domain, helped secure the contract.
ROC Fraud Management is Subex's award-winning solution that helps wireless and wireline operators eliminate known frauds, uncover new fraud patterns, minimise fraud run time, augment internal controls and support continuous fraud management process improvement.
ROC revenue assurance is designed not only to detect potential revenue loss, but also to assist an operator with its investigation, diagnosis and recovery of these revenues. It provides unprecedented automated correction capabilities to improve bottom-line results and provide a quick return-on-investment.
In the late afternoon, Subex was trading at around Rs28 per share on the Bombay Stock Exchange, 2.69% down from the previous close.
On 30th November, Ranbaxy had launched Atorvastatin, a generic version of Lipitor in the US market
Gurgaon-based Ranbaxy Laboratories Ltd has launched Atorvastatin Basics, a generic version of the cholesterol lowering drug Sortis in the German market.
Atorvastatin Basics is launched in the strength of 10mg, 20mg, 40mg and 80mg.
Ranbaxy had obtained, pursuant to a settlement agreement with Pfizer, the rights to an early entry of Atorvastatin in the German market. Pfizer's patent for Sortis expires in Germany on 7th May. Daiichi Sankyo Deutschland GmbH will assist in the launch of Atorvastatin Basics. Daiichi Sankyo has a substantial reach amongst cardiologists and physicians in the German market.
Apart from Germany, Daiichi Sankyo and Ranbaxy are working on synergies in other countries, such as India, Romania, Italy and Mexico, among others.
Earlier on 30th November, Ranbaxy had launched Atorvastatin, a generic version of Lipitor in the US market with 180 days of marketing exclusivity, as it was a first-to-file (FTF) applicant on the product. Recently, Ranbaxy also introduced generic Atorvastatin in Australia with three months exclusivity.
In the late afternoon, Ranbaxy was trading at around Rs411 per share on the Bombay Stock Exchange, 1.57% down from the previous close.
The program aims to build a pool of modern banking professionals for Axis Bank
Axis Bank and NIIT Institute of Finance, Banking & Insurance Training Ltd (IFBI) has launched post graduate diploma in retail banking (PGDRB), a career program designed for Axis Bank. The program aims to build a pool of modern banking professionals for Axis Bank. To this end, IFBI has designed a comprehensive program that builds competencies on 4 dimensions—domain, application, technology and customer-service needed by banking professionals.
Admission to the PGDRB Program will be through admission test and interview. The selected candidates will be provided with provisional appointment letters at the time of enrolment, and after successful completion of the program will join Axis Bank at the officer level.
After completion of the program students will join Axis Bank as front desk officers who are the first point of contact for customers.
In the late afternoon, Axis Bank was trading at around Rs1,160 per share on the Bombay Stock Exchange, 0.9% up from the previous close.